Arcellx (ACLX) Capital Leases (2022 - 2023)
Arcellx's (ACLX) quarterly Capital Leases came in at $5.8 million in Q3 2023, down 78.73% year-on-year from $27.1 million in Q3 2022, and down 34.91% quarter-over-quarter from $8.8 million in Q2 2023.
Arcellx (ACLX) Capital Leases (2022 - 2023) Analysis & Trends
Arcellx's Capital Leases history runs 2 years deep, the most recent figure standing at $5.8 million for Q3 2023.
- On a quarterly basis, Capital Leases fell 78.73% year-over-year to $5.8 million in Q3 2023; TTM through Sep 2023 was $5.8 million, a 78.73% decrease from a year earlier, with the FY2022 full-year figure at $20.9 million, changed N/A from the prior year.
- Capital Leases fell to $5.8 million in Q3 2023 per ACLX's latest filing, from $8.8 million in the prior quarter.
- Across five years, Capital Leases topped out at $27.1 million in Q3 2022 and bottomed at $5.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 8.84 Mn |
| Mar 31, 2023 | 15.41 Mn |
| Dec 31, 2022 | 20.87 Mn |
| Sep 30, 2022 | 27.05 Mn |